Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer
Clinical trial NCT00179699 · TERMINATED
Trial details
- NCT number
- NCT00179699
- Sponsor
- Celgene Corporation
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2005-09-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.